You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

neurokinin 1 receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Epidermolysis Bullosa Trial in Redwood City (Serlopitant Tablet, Placebo Oral Tablet)

Completed
Has Results
  • Epidermolysis Bullosa
  • Serlopitant Tablet
  • Placebo Oral Tablet
  • Redwood City, California
    Stanford University
Nov 30, 2022

Gynecologic Cancer Trial in Ann Arbor (Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA))

Recruiting
  • Gynecologic Cancer
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Jan 6, 2022

Prurigo Nodularis Trial in Germany (serlopitant, Placebo)

Completed
Has Results
  • Prurigo Nodularis
  • Berlin-Mitte, Germany
  • +14 more
May 18, 2021

Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus Trial in Lahore (NK-1R antagonist)

Unknown status
  • Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus
  • NK-1R antagonist
  • Lahore, Punjab, Pakistan
    Bahria International Hospital
Jul 10, 2020

Epidermolysis Bullosa, Pruritus Trial in Stanford (VPD-737, Placebo)

Completed
Has Results
  • Epidermolysis Bullosa
  • Pruritus
  • Stanford, California
    Stanford
Mar 10, 2020

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Incidence of Retained Gastric Food on Endoscopy

Not yet recruiting
  • Gastric Content Aspiration
  • Esophagogastroduodenoscopy
  • (no location specified)
May 16, 2023

Caveolin 1 Deficiency in Response to Glucagon-like Peptide 1

Not yet recruiting
  • Overweight and Obesity
  • 24-hour ambulatory blood pressure
  • Liberal salt diet
  • (no location specified)
Oct 4, 2023

Breast Cancer, Chemo-induced Nausea and Vomiting Trial in Hanzhou (Aprepitant, Palonosetron, Fosaprepitant)

Not yet recruiting
  • Breast Cancer
  • Chemotherapy-induced Nausea and Vomiting
  • Hanzhou, Zhejiang, China
    the Second Affiliated Hospital of Zhejiang Univercity School of
Apr 23, 2023

Preoperative Prandial State of Patients Taking Glucagon-Like

Recruiting
  • Pulmonary Aspiration
  • Gastric ultrasound
  • Houston, Texas
    The University of Texas Health Science Center at Houston
Jun 6, 2023

MS Patients Treated With Sphingosine-1-phosphate Receptor

Recruiting
  • Multiple Sclerosis
  • S1PR analysis on immune cells
  • Bern, Switzerland
    Neurology department
Apr 12, 2023

Muscarinic Receptor Occupancy Trial in New Haven (Scopolamine, [11C]EMO ([11C]LSN3172176))

Not yet recruiting
  • Muscarinic Receptor Occupancy
  • New Haven, Connecticut
    Yale University
Aug 31, 2023

Diabetes Trial in Nanjing (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc)

Recruiting
  • Diabetes
  • Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
  • Nanjing, China
    Nanjing First Hospital, Nanjing Medical Univesity
Aug 6, 2023

Glucagon-like Peptide 1 Receptor Agonists and Mental Health

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • GLP-1 receptor agonist
  • (no location specified)
Aug 4, 2022

Type 2 Diabetes Trial in Lancaster (Exenatide Injection, Saline injection)

Terminated
  • Type 2 Diabetes
  • Exenatide Injection
  • Saline injection
  • Lancaster, Pennsylvania
    Amish Research Clinic
Mar 6, 2023

Therapeutic Drug Use for CKD Patients

Active, not recruiting
  • Chronic Kidney Disease
  • angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
  • Jinan, Shandong, China
    Xiao Li，MD
Apr 18, 2023

Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

Not yet recruiting
  • Digestive System Neuroendocrine Tumor G1
  • +5 more
  • Tumor Debulking
  • +5 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Aug 23, 2023

Osteoporosis, Postmenopausal, Diabetes, Type 2 Trial in Jackson (GLP-1 receptor agonist)

Recruiting
  • Osteoporosis, Postmenopausal
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Jackson, Mississippi
    University of Mississippi Medical Center
Aug 5, 2022

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

Not yet recruiting
  • Neuroendocrine Tumor (NET)
  • Colorectal Cancer (CRC)
  • CHM-2101 CAR-T cells
  • (no location specified)
Sep 20, 2023

Stroke, Stroke, Acute, Stroke, Ischemic Trial in Linyi, Hong Kong (Semaglutide)

Recruiting
  • Stroke
  • +3 more
  • Linyi, Shangdong, China
  • +1 more
Jun 24, 2023

Primary Aldosteronism Trial in Montréal (Renin measurements)

Not yet recruiting
  • Primary Aldosteronism
  • Renin measurements
  • Montréal, Quebec, Canada
    Hôpital du Sacré-Coeur de Montréal
Oct 30, 2023

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

C.Surgical Procedure; Gastrointestinal Trial in Guangzhou (palonosteron, dexamethasone, and fosaprepitant dissolved in 0.9%

Completed
  • C.Surgical Procedure; Gastrointestinal
  • palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl
  • palonosetron, dexamethasone, and 0.9% NaCl
  • Guangzhou, Guangdong, China
    The Sixth Affiliated Hospital of Sun Yat-sen University
Dec 26, 2022